🔴 Definium Therapeutics is trading 4.45% down amid biotech-sector weakness

Definium Therapeutics is trading 4.45% lower at $33.53 on October 8, 2026, amid biotech-sector weakness and broader risk-off pressure.

• XBI is down 2.04%; geopolitical tensions, higher oil prices and elevated Treasury yields are contributing to broader risk-off pressure.
• No company-specific announcement explaining the decline surfaced in the available search; recent indexed releases concern earlier clinical-trial updates, not a new event on October 8.
• Available evidence points to sector and market sentiment rather than a company-specific catalyst.